Jump to content
RemedySpot.com

Update Confirms PROVENGE Improves Overall CaP Survival

Rate this topic


Guest guest

Recommended Posts

Guest guest

Updated results from its pivotal Phase 3 IMPACT (IMmunotherapy for

Prostate AdenoCarcinoma Treatment) study demonstrate that PROVENGE*

(sipuleucel-T) extends overall survival in men with metastatic,

castrate-resistant (hormone-refractory) prostate cancer

(CRPC). The data will be presented at the American Society of Clinical

Oncology 2010 Genitourinary Cancers Symposium (ASCO-GU) in San

Francisco on Friday, March 5 at 1:45 pm PT.....Click on the below link for the full story:<http://www.medicalnewstoday.com/articles/181163.php>

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...